Spyre Therapeutics (SYRE) presented its combination-biologics strategy at the Wells Fargo 21st Annual Healthcare Conference, with CEO Cameron Turtle and SVP of Clinical Development Josh Friedman outlining pipeline progress across inflammatory bowel disease (IBD), hidradenitis suppurativa (HS), and other autoimmune indications.
Spyre holds approximately $1.1 billion in cash on hand, management said, providing a runway through expected clinical readouts in 2027. The company's shares trade around $86.93, up roughly 165% year-to-date, with a market capitalization of $7.66 billion. Wells Fargo analyst Yanan Zhu maintains a strong-buy consensus, setting a price target range of $97 to $130.
Spyre's lead asset is SPY007, a long-acting IL-17AF antibody, paired with a TL1A-targeting molecule. The company is pursuing co-formulated combinations rather than bispecific antibodies. Turtle said bispecifics carry higher risks for increased immunogenicity, reduced avidity and shorter half-lives compared with long-acting monotherapies, calling the co-formulation approach "the highest probability way of getting to that product."
The SKYLINE global Phase II study in IBD is split into two parts. Enrollment for Part A's monotherapy arms finished in April. Part B — expected to deliver an induction readout in 2027, with maintenance data following roughly nine months later — will test all three monotherapies at two doses plus all three pairwise combinations at high doses, totaling six active agents against a placebo group in a single readout. The trial is running at roughly 260 of 500 global IBD study sites across a dozen countries.
Turtle noted that new IBD products generally need to beat the standard of care by about 10 percentage points on clinical remission to capture meaningful market share. The top three IBD drugs — Takeda's ENTYVIO (vedolizumab), Merck's TREMFYA, and Johnson & Johnson's STELARA — control roughly 70% of the market, Spyre said.
For rheumatoid arthritis, Turtle acknowledged that monotherapy efficacy "didn't quite meet that bar," but described SPY007 as one of the few RA products that beats placebo on multiple endpoints without safety downsides, suggesting it remains a strong combination component.
In HS, the SKYLIGHT trial targets HiSCR 75 as its primary endpoint. Friedman said a positive SKYLIGHT 1 result would trigger initiation of SKYLIGHT 2. Expected data readouts across the broader pipeline include TL1A in psoriatic arthritis and axial spondyloarthritis in Q4 2024, along with TL1A in atopic dermatitis and metabolic associated fatty liver disease (MASH).
In psoriatic arthritis, Turtle cited an efficacy bar of approximately 30/20/10 on ACR endpoints plus PASI 75 for skin benefit. Spyre also has programs targeting alpha-4 beta-7, IL-23 and IL-17AF being evaluated across indications including Crohn's disease, ulcerative colitis, psoriasis and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
